Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

  1. Martinez-Lopez, J.
  2. Sanchez-Vega, B.
  3. Barrio, S.
  4. Cuenca, I.
  5. Ruiz-Heredia, Y.
  6. Alonso, R.
  7. Rapado, I.
  8. Marin, C.
  9. Cedena, M.-T.
  10. Paiva, B.
  11. Puig, N.
  12. Mateos, M.-V.
  13. Ayala, R.
  14. Hernández, M.-T.
  15. Jimenez, C.
  16. Rosiñol, L.
  17. Martínez, R.
  18. Teruel, A.-I.
  19. Gutiérrez, N.
  20. Martin-Ramos, M.-L.
  21. Oriol, A.
  22. Bargay, J.
  23. Bladé, J.
  24. San-Miguel, J.
  25. Garcia-Sanz, R.
  26. Lahuerta, J.-J.
  27. Erakutsi egile guztiak +
Aldizkaria:
Leukemia

ISSN: 1476-5551,  0887-6924

Argitalpen urtea: 2017

Alea: 31

Zenbakia: 6

Orrialdeak: 1446-1449

Mota: Gutuna

DOI: 10.1038/LEU.2017.58 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus